Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Am Pharm Assoc (2003) ; 60(6): e349-e356, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32819878

RESUMEN

OBJECTIVES: The primary objectives of this study were to (1) reduce pharmacy turnaround time (TAT) without compromising safety and quality and (2) reduce compounding order overload during peak hours (8:00 AM-5:00 PM). The secondary objective was to decrease patient wait time pertinent to pharmacy services. SETTING: The setting was a hospital-based pharmacy. PRACTICE DESCRIPTION: Pharmacy dispensing more than 1800 doses daily, 30% of which goes to outpatient cancer treatment. Patients usually receive multiple compounded medications; thus, compounding numbers are several folds higher than patient number. High compounded chemotherapy order volume overloaded pharmacy staff during peak hours and was a major contributor to patient wait time. PRACTICE INNOVATION: Using Define Measure Analyze Improve Control Six Sigma and intelligent risk-taking strategies, a dedicated team identified root causes of problems and designed long-lasting solutions that would not compromise quality. EVALUATION: The most effective initiative was the advanced preparation of chemotherapy for select patients (Concierge), which addressed pharmacy TAT, patient wait time, and chemotherapy order overload, all without affecting safety or quality of dispensed medications. RESULTS: Pharmacy TAT decreased by 77% for Concierge patients and 31% for standard patients. Comparable decreases were observed for patient wait time: 67% for Concierge and 27% for standard patients. Safety and quality were maintained for all dispensations during and after implementation of Concierge. A concurrent 8% increase in patient number was observed despite no changes in physical capacity. CONCLUSION: The implementation of Concierge initiatives: markedly reduced pharmacy TAT without compromising safety checks performed by pharmacists; decreased chemotherapy order overload during peak hours; improved distribution of assignments for pharmacy staffand statistically significant decreased wait time for all patients, especially those selected for Concierge. Effective selection of Concierge patients minimized additional costs associated with wasted premixed chemotherapy. Improving workflow for a subset of patients affected a greater patient population, allowing additional patients to be treated daily.


Asunto(s)
Servicios Farmacéuticos , Farmacias , Farmacia , Humanos , Farmacéuticos , Flujo de Trabajo
2.
J Zoo Wildl Med ; 45(4): 935-40, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25632687

RESUMEN

Lymphoma is a common malignancy observed in companion animals. This type of naturally occurring neoplasia has been uncommonly reported in great apes. Diffuse large B-cell lymphoma was diagnosed in an 8-yr-old captive orangutan (Pongo pygmaeus) with gastrointestinal disease by histologic and immunohistochemical methodologies. The orangutan was treated with three cycles of combination chemotherapy (intravenous Rituxan, cyclophosphamide, doxorubicin, and vincristine). The primate has been in good health and exhibiting normal behaviors for more than 15 mo following treatment.


Asunto(s)
Enfermedades del Simio Antropoideo/diagnóstico , Neoplasias del Yeyuno/veterinaria , Linfoma de Células B/veterinaria , Pongo , Animales , Animales de Zoológico , Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Enfermedades del Simio Antropoideo/tratamiento farmacológico , Enfermedades del Simio Antropoideo/cirugía , Ciclofosfamida/uso terapéutico , Doxorrubicina/uso terapéutico , Femenino , Neoplasias del Yeyuno/diagnóstico , Neoplasias del Yeyuno/tratamiento farmacológico , Neoplasias del Yeyuno/cirugía , Linfoma de Células B/diagnóstico , Linfoma de Células B/tratamiento farmacológico , Linfoma de Células B/cirugía , Prednisona/uso terapéutico , Rituximab , Vincristina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA